• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1337607 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: j) E8 y1 K$ r) ~) F/ aNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
( ]  k" k4 }5 q8 S' Z5 ?* Q9 q+ Author Affiliations* \# Q) r5 r8 F* B( i
( P* E) v; |+ [9 w7 O6 o
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
3 k; r/ E& h5 D) e) L2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan $ B$ G# V" @: H5 T% e  ^
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( j4 Y& G& i& x  Q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
# z, P; v) [0 B: i5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 9 ]$ p+ o, a8 t/ C) h% x, L
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ; b1 Z1 I9 D; u$ P0 V! ?" N$ B
7Kinki University School of Medicine, Osaka 589-8511, Japan # n( |4 b8 w. E& D0 v9 t9 u
8Izumi Municipal Hospital, Osaka 594-0071, Japan 9 E- O! K) t9 Z! z& f% ~
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 6 ^4 |; a1 Z3 B- N) e+ S1 a
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 6 }, q! L- d) Z2 l3 W
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. . M& S- Q& A2 L3 F! X! g8 N: ^2 o6 _
9 E; G4 N2 B2 N2 }( X' B/ h5 t
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type : Z3 l+ B8 W4 \: R4 ]4 n5 A4 B+ z
3 A( l- W) O$ r% y
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato % {: F+ v0 }& Z) E) A! ~/ G
6 U% N: y* f8 R# q5 n* e' s
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
4 v' q$ o, ^1 H/ d% |, J- _4 J6 n$ |- e$ C, |0 i  I
Published online on: Thursday, December 1, 2011 , U( j8 @; m! P" A3 W( L* A
; G# n5 R- E2 Q- i* |
Doi: 10.3892/ol.2011.507
+ N; _  m. n, A( ]% f7 ~. f3 \1 E; l$ I7 |, J' Y
Pages: 405-410
/ M) |' ^$ G5 I" P
9 A6 v" X- V- N5 n5 [4 ?/ ^: O: J' b2 ~Abstract:
7 {* x7 a3 q% \) q  U! o# E: E8 N$ C& YS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma., t- f& A9 m. {8 d" u, u4 O5 C
# D, t' a' T" c- G& ?8 T/ |+ U
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
5 p: H) ]5 c: g" m/ iF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
* P  q/ B+ U; H  l+ Author Affiliations, Z0 s0 |; L$ B  J# p: D- ^
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
2 [8 U- Z2 W2 W8 t2Department of Thoracic Surgery, Kyoto University, Kyoto 6 a, m' K. Z1 Z( B6 E$ e
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
4 }: j, Z2 _4 Z( m. f&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
* A9 x" p9 U$ s! l' |/ E8 K" rReceived September 3, 2010.
: c- R6 }" _0 o5 xRevision received November 11, 2010. ' E; F& I4 c# Y6 ~' m
Accepted November 17, 2010.
/ Z4 ~) m. `$ yAbstract, R8 X9 Q5 r8 |) X5 b( h5 O/ q
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
* p8 O6 C. R6 @3 ZPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. ; E' U. ]% Y3 A$ f
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
. \- x! O& ^' K: A9 x! M: a) XConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
' v- n) @; S% R
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
' ?* a: r; ~) e: X, b今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?: a5 E3 ]3 h) l+ b
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy9 F6 m5 Y, ]  K
http://clinicaltrials.gov/ct2/show/NCT01523587+ l, ?+ f: d. T9 I$ k$ K

+ y2 v+ S( ~$ S  e, }9 `BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
" `1 o# s+ u" t  [http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 4 A/ H, _. z) ^8 h2 W1 W- m2 h
$ V% h& R) V+ n2 ^! e: M& [
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。9 L8 K& W' ]  W9 b4 C. u
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 6 N1 ^; _) I; p5 P$ [
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
$ V! O+ N# d  `1 v至今为止,未出 ...

+ i& _5 M: K" [6 j0 I! r. p( E没有副作用是第一追求,效果显著是第二追求。
) K' B1 t8 Z: k8 A3 [不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表